TXG logo

10x Genomics (TXG)

Profile

Full Name

10x Genomics, Inc.

Ticker Symbol

TXG

Exchange

NASDAQ

Sector

Healthcare

Industry

Health Information Services

Country

United States

IPO

September 12, 2019

Indexes

Not included

Website

http://www.10xgenomics.com

Employees

1306

Key Details

Price

$8.43(+4.07%)

Market cap

Last Dividend

-

TTM Dividend yield

-

Annual revenue

$610.78M(-1.28% YoY)

Annual EPS

-$1.52(+30.28% YoY)

PE ratio

-

Next earnings date

May 8, 2025

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Current Price

$8.43
TXG price is $8.43

30-Day Relative Volume

0.85
TXG 30-day relative volume is 0.85

Price Performance

Price Most recent change

+4.07%
TXG price was up +4.07% on May 2, 2025

Price YTD change

-41.3%
TXG price is down -41.3% since January 1st

Price 1-year change

-67.93%
TXG price is down -67.93% year-on-year

Price 3-year change

-83.42%
TXG price is down -83.42% over the past 3 years

Price Range

Price All-time high

$208.99
TXG price is currently -95.97% below its historical high of $208.99

Price 3-year low

$6.78
TXG price is currently +24.34% above its 3-year low

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Market cap

$1.03B
TXG market capitalization is $1.03 billion

Market cap 3-year change

-82.12%
TXG market capitalization is down -82.12% over the past 3 years

Market cap All-time high

$22.11B
TXG market capitalization is currently -95.34% below its historical high of $22.11 billion

Market cap sector rank

75.98%
TXG market capitalization is higher than 75.98% of companies in Healthcare sector

Shares Outstanding

Shares Outstanding 1-Year Change

+2.17%
TXG shares outstanding is up +2.17% year-on-year

Shares Outstanding 3-Year Change

+7.88%
TXG shares outstanding is up +7.88% over the past 3 years

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Beta

1.81
TXG beta is 1.81

200-day SMA

$15.38
TXG price is currently -45.19% below its 200-day simple moving average

50-day SMA

$9.36
TXG price is currently -9.98% below its 50-day simple moving average

RSI

48.02
TXG 14-day relative strength index is 48.02

Volume

0.85
TXG 30-day relative volume is 0.85

ATR

$0.54
TXG average true range is $0.54

10-day Historical Volatility

36.29%
TXG 10-day historical volatility is 36.29%

Dividend

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Revenue

$610.78M
TXG annual revenue is $610.78 million

Revenue Analysts estimate

$609.61M
TXG annual revenue is currently +0.19% higher than the consensus analysts' forecast

Revenue 1-year change

-1.28%
TXG annual revenue is down -1.28% year-on-year

Revenue Sector rank

75.48%
TXG annual revenue is higher than 75.48% of companies in Healthcare sector

EPS

EPS

-$1.52
TXG annual earnings per share is -$1.52

EPS Analysts estimate

-$0.54
TXG annual earnings per share is currently +184.11% higher than the consensus analysts' forecast

EPS 1-year change

+30.28%
TXG annual earnings per share is up +30.28% year-on-year

EPS Sector rank

45.04%
TXG annual earnings per share is higher than 45.04% of companies in Healthcare sector

Profit

Gross profit

$414.48M
TXG annual gross profit is $414.48 million

Gross margin

67.86%
TXG annual gross profit margin is 67.86%

Operating profit

-$194.56M
TXG annual operating income is -$194.56 million

Operating margin

-31.85%
TXG annual operating profit margin is -31.85%

Net income

-$182.63M
TXG annual net profit is -$182.63 million

Net margin

-29.90%
TXG annual net profit margin is -29.90%

Expenses

Total expenses

$805.34M
TXG annual total expenses is $805.34 million

Operating expenses

$609.04M
TXG annual total operating expenses is $609.04 million

Cost of goods sold

$196.30M
TXG annual cost of goods sold is $196.30 million

Selling, general & administrative expenses

$344.34M
TXG annual SGA is $344.34 million

Depreciation and amortization

$43.71M
TXG annual depreciation & amortization is $43.71 million

Interest expense

$4000.00
TXG annual interest expense is $4000.00

Income tax

$4.93M
TXG annual income tax is $4.93 million

EBIT & EBITDA

EBIT

-$177.70M
TXG annual earnings before interest & taxes is -$177.70 million

EBITDA

-$133.99M
TXG annual EBITDA is -$133.99 million

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Total assets

$918.64M
TXG annual total assets is $918.64 million

Non current assets

$334.25M
TXG annual long term assets is $334.25 million

Current assets

$584.39M
TXG annual total current assets is $584.39 million

Cash and cash equivalents

$344.07M
TXG annual cash & cash equivalents is $344.07 million

Accounts receivable

$87.86M
TXG annual accounts receivable is $87.86 million

Inventory

$83.11M
TXG annual inventory is $83.11 million

Liabilities

Total liabilities

$208.50M
TXG annual total liabilities is $208.50 million

Long term liabilities

$90.87M
TXG annual total long term liabilities is $90.87 million

Current liabilities

$117.63M
TXG annual total current liabilities is $117.63 million

Accounts payable

$12.91M
TXG annual accounts payable is $12.91 million

Debt

Total debt

$82.61M
TXG annual total debt is $82.61 million

Total debt 1-year change

-13.38%
TXG annual total debt is down -13.38% year-on-year

Long term debt

$73.33M
TXG annual long term debt is $73.33 million

Short term debt

$9.29M
TXG annual short term debt is $9.29 million

Equity & Capital

Shareholders equity

$710.13M
TXG annual stockholders equity is $710.13 million

Book value

$710.13M
TXG annual book value is $710.13 million

Retained earnings

-$1.47B
TXG annual retained earnings is -$1.47 billion

Working capital

$466.75M
TXG annual working capital is $466.75 million

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Cash from operations

$6.66M
TXG annual cash flow from operations is $6.66 million

Cash from operations 1-year change

+143.85%
TXG annual cash flow from operations is up +143.85% year-on-year

Cash from investing

-$32.63M
TXG annual cash flow from investing activities is -$32.63 million

Cash from investing 1-year change

-124.44%
TXG annual cash flow from investing activities is down -124.44% year-on-year

Cash from financing

$10.91M
TXG annual cash flow from financing activities is $10.91 million

Cash from financing 1-year change

-20.16%
TXG annual cash flow from financing activities is down -20.16% year-on-year

CAPEX

CAPEX

$13.39M
TXG annual capital expenditures is $13.39 million

CAPEX 1-year change

-72.96%
TXG annual capital expenditures is down -72.96% year-on-year

Free Cash Flow

Free cash flow

-$6.73M
TXG annual free cash flow is -$6.73 million

Free cash flow 1-year change

+89.6%
TXG annual free cash flow is up +89.6% year-on-year

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

Gross margin

67.86%
TXG annual gross profit margin is 67.86%

Operating margin

-31.85%
TXG annual operating profit margin is -31.85%

Net margin

-29.90%
TXG annual net profit margin is -29.90%

ROA & ROE

ROA

-19.39%
TXG annual return on assets is -19.39%

ROE

-25.17%
TXG annual return on equity is -25.17%

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE ratio

-
TXG price to earnings ratio value is unknown

PE ratio Sector rank

-
TXG price to earnings ratio is unknown

PB Ratio

PB ratio

1.45
TXG price to book ratio is 1.45

PB ratio Sector rank

50.29%
TXG price to book ratio is higher than 50.29% of companies in Healthcare sector

PS Ratio

PS ratio

1.69
TXG price to sales ratio is 1.69

PS ratio Sector rank

37.31%
TXG price to sales ratio is higher than 37.31% of companies in Healthcare sector

Enterprise value

Enterprise value

$769.55M
TXG enterprise value is $769.55 million

Enterprise value Sector rank

72.39%
TXG enterprise value is higher than 72.39% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

-5.74
TXG EV/EBITDA is -5.74

EV/EBITDA Sector rank

19.72%
TXG EV/EBITDA is higher than 19.72% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Current ratio

4.97
TXG annual current ratio is 4.97

Quick ratio

4.26
TXG annual quick ratio is 4.26

Leverage

Debt to equity

0.00
TXG annual debt to equity ratio is 0.00

Interest coverage ratio

-44.42K
TXG annual interest coverage ratio is -44.42 thousand

Risk & Stability

Piotroski F-Score

6
TXG piotroski f-score is 6

Altman Z-Score

1.37
TXG altman z-score is 1.37

Analyst ratings

Recent major analysts updates

Apr 10, 25 Barclays
Overweight
Mar 4, 25 Citigroup
Buy
Feb 14, 25 Morgan Stanley
Overweight
Feb 14, 25 Barclays
Overweight
Feb 13, 25 UBS
Neutral
Feb 13, 25 Stifel
Buy
Feb 13, 25 Leerink Partners
Market Perform
Feb 13, 25 JP Morgan
Neutral
Feb 13, 25 Citigroup
Buy
Feb 13, 25 Canaccord Genuity
Buy

Institutional Ownership

Similar stocks

NVAX logo
Novavax (NVAX)
HSTM logo
HealthStream (HSTM)
ELVN logo
Enliven Therapeutics (ELVN)
PHVS logo
Pharvaris NV (PHVS)
MLYS logo
Mineralys Therapeutics (MLYS)
NEO logo
NeoGenomics (NEO)
ARDX logo
Ardelyx (ARDX)
HCSG logo
Healthcare Services (HCSG)
AORT logo
Artivion (AORT)
  • What is the ticker symbol for 10x Genomics?
  • Does 10x Genomics pay dividends?
  • What sector is 10x Genomics in?
  • What industry is 10x Genomics in?
  • What country is 10x Genomics based in?
  • When did 10x Genomics go public?
  • Is 10x Genomics in the S&P 500?
  • Is 10x Genomics in the NASDAQ 100?
  • Is 10x Genomics in the Dow Jones?
  • When was 10x Genomics's last earnings report?
  • When does 10x Genomics report earnings?
  • Should I buy 10x Genomics stock now?

What is the ticker symbol for 10x Genomics?

The ticker symbol for 10x Genomics is NASDAQ:TXG

Does 10x Genomics pay dividends?

No, 10x Genomics does not pay dividends

What sector is 10x Genomics in?

10x Genomics is in the Healthcare sector

What industry is 10x Genomics in?

10x Genomics is in the Health Information Services industry

What country is 10x Genomics based in?

10x Genomics is headquartered in United States

When did 10x Genomics go public?

10x Genomics's initial public offering (IPO) was on September 12, 2019

Is 10x Genomics in the S&P 500?

No, 10x Genomics is not included in the S&P 500 index

Is 10x Genomics in the NASDAQ 100?

No, 10x Genomics is not included in the NASDAQ 100 index

Is 10x Genomics in the Dow Jones?

No, 10x Genomics is not included in the Dow Jones index

When was 10x Genomics's last earnings report?

10x Genomics's most recent earnings report was on Feb 12, 2025

When does 10x Genomics report earnings?

The next expected earnings date for 10x Genomics is May 8, 2025

Should I buy 10x Genomics stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
On this page